Politics, Policy & Law
Largely aspirational, Biden’s COVID-19 strategy hints at chance for long-term impact on drug development
The question is whether plans for expansion of data, diagnostics and health equity will come to fruition
The question is whether plans for expansion of data, diagnostics and health equity will come to fruition.
The Biden administration’s strategy for COVID-19 and long-term pandemic preparedness is in large part a plan for a plan, but it contains kernels of concepts that if fully developed could transform how drug companies conduct clinical trials, use real-world data, and reach into underserved communities.
Among the 200 pages of President Joe Biden’s National Strategy for the COVID-19 Response and Pandemic Preparedness are three areas beyond vaccine development and distribution that could present meaningful long-term change for biopharmas and patients if taken to the limit: testing and diagnostics, data collection and integration, and health equity.
The challenge will be exactly that